Fundraising Fox

Philip Astley-Sparke

Investor

Venture Partner at Forbion

Boston, Massachusetts

Writes $100K – $5M checks Β· typically $1.5M

About

Philip Astley-Sparke is Executive Chairman and co-founder of Replimune, a developer of oncolytic vaccines. He previously served as President and CEO of BioVex, which brought Imlygic to FDA approval in 2015 before its acquisition by Amgen in 2011, and as President of uniQure, where he established U.S. operations including a gene therapy manufacturing facility. Astley-Sparke holds a BSc in Cellular and Molecular Pathology from Bristol University, qualified as a Chartered Accountant, and has experience as a healthcare investment banker.

Skills & more

Biotechnology18Commercialization11Lifesciences9Vaccines8Clinical Trials7Life Sciences6Oncology6Mergers & Acquisitions3Biopharmaceuticals3FDA3Start-ups2Clinical Development2
+4 moreImmunologyMergersStrategyPharmaceutical Industry

From Philip's professional profile.

Colleagues at Forbion

Frequently asked questions

Who is Philip Astley-Sparke?
Philip Astley-Sparke is Executive Chairman and co-founder of Replimune, a developer of oncolytic vaccines. He previously served as President and CEO of BioVex, which brought Imlygic to FDA approval in 2015 before its acquisition by Amgen in 2011, and as President of uniQure, where he established U.S. operations including a gene therapy manufacturing facility. Astley-Sparke holds a BSc in Cellular and Molecular Pathology from Bristol University, qualified as a Chartered Accountant, and has experience as a healthcare investment banker.
Where does Philip Astley-Sparke work?
Philip Astley-Sparke is Venture Partner at Forbion.
What check size does Philip Astley-Sparke write?
Philip Astley-Sparke typically writes checks of $100K – $5M.